Provided by Tiger Trade Technology Pte. Ltd.

Repligen

173.71
-1.0200-0.58%
Volume:208.35K
Turnover:36.40M
Market Cap:9.78B
PE:237.96
High:178.55
Open:174.90
Low:172.70
Close:174.73
52wk High:188.73
52wk Low:100.99
Shares:56.29M
Float Shares:53.32M
Volume Ratio:0.57
T/O Rate:0.39%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.7300
EPS(LYR):0.8600
ROE:1.99%
ROA:1.40%
PB:4.63
PE(LYR):201.99

Loading ...

BioLife Details Strategic Repligen Merger Communication to Staff

TIPRANKS
·
Aug 04

Repligen Says BioLife Deal Targets Q4 Close Pending Regulatory, Shareholder Approvals

Reuters
·
Aug 04

Repligen is Maintained at Overweight by Wells Fargo

Dow Jones
·
Jul 30

Switzerland's Bachem H1 Sales Rise 4.3% on Growth in Clinical Drug Development

Reuters
·
Jul 30

Beta Bionics Q2 Sales Beat Estimates on Pharmacy Channel Growth

Reuters
·
Jul 30

Analysts’ Top Healthcare Picks: Repligen (RGEN), Allogene Therapeutics (ALLO)

TIPRANKS
·
Jul 30

Repligen's Diversity of Growth Drivers Support Return to Mid-Teens Organic Sales Growth, RBC Says

MT Newswires Live
·
Jul 30

Repligen’s Operational Momentum Offset by Full Valuation; Kyle Mikson CFA Reiterates Hold with Unchanged $145 Price Target

TIPRANKS
·
Jul 29

Repligen Stock (RGEN) Rises After Investors Wowed By ‘Market Leading’ Q2 Figures

TIPRANKS
·
Jul 29

RBC Raises Price Target on Repligen to $185 From $160, Keeps Outperform Rating

MT Newswires Live
·
Jul 29

Analysts Offer Insights on Healthcare Companies: Repligen (RGEN) and Envista Holdings (NVST)

TIPRANKS
·
Jul 29

UK's Abingdon Health Expects FY26 Revenue up 31%

Reuters
·
Jul 29

Repligen Corp : JP Morgan Raises Target Price to $175 from $165

THOMSON REUTERS
·
Jul 29

Repligen Corp : Leerink Partners Raises Target Price to $220.00 from $200.00

THOMSON REUTERS
·
Jul 29

Ashland Q3 Profit Beats on Higher Volume, Pricing; Cuts FY EPS Forecast

Reuters
·
Jul 29

Repligen rises 15.4%

TIPRANKS
·
Jul 29

Repligen up over 15%, on Pace for Largest Percent Increase Since July 2024

Dow Jones
·
Jul 28

Movement Alert|Repligen Rises 15.35% in Regular Trading, Q2 Earnings Significantly Beat Expectations with Full-Year Guidance Raised

Market Focus
·
Jul 28

Repligen Earns Buy Rating on Strong Q2 Beat, Raised Guidance, and Broad-Based Demand Strength

TIPRANKS
·
Jul 28

Repligen Corp Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 28